Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two The… (NCT07282548) | Clinical Trial Compass
WithdrawnNot Applicable
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
Stopped: Withdrawn prior to enrolment after review of updated safety data
0Started 2026-06
Plain-language summary
This study aims to evaluate how well the effectiveness of the medicine Tazemetostat works in adults with relapsed/refractory follicular lymphoma, a slow-growing type of blood cancer that affects a kind of white blood cell called lymphocytes.
All participants will receive Tazemetostat as prescribed by their doctor in the routine clinical practice.
The study will observe how participants respond to the treatment, how long the response lasts, and monitor safety, side effects and how well participants tolerate the treatment.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18 years or older
* Histologically confirmed follicular lymphoma grades 1, 2, or 3A
* At least two prior lines of systemic therapy
* Prescribed tazemetostat according to United States prescribing information (USPI)
* Known or planned EZH2 mutation status
* Signed informed consent
Exclusion Criteria:
* Grade 3B or transformed follicular lymphoma
* Other hematologic malignancies
* Use of strong/moderate Cytochrome P450 (CYP3A) inhibitors
* Pregnant or breastfeeding
* Participation in another investigational program
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Real-world Objective Response Rate (rwORR) stratified by EZH2 mutation status.
Timeframe: Fom first dose to end of study participation, which may range from 1 day to up to 5 years.